Tilray announced the successful import of its Tilray 2:100 product into the United Kingdom.
Tilray (NASDAQ:TLRY) announced the successful import of its Tilray 2:100 cannabidiol (CBD) oil product into the UK to supply a pediatric patient.
As quoted in the press release:
The changing regulatory measures in the United Kingdom (UK) previously prohibited the use of medical cannabis. However, in July 2018, Home Secretary Sajid Javid announced that clinicians will now legally be able to prescribe cannabis-derived medicines to patients with an exceptional clinical need noting “recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory.”
With government-approved compassionate access, the UK-based patient suffering from a rare form of epilepsy, now has reliable access to Tilray 2:100, the product used as the primary medicine in a clinical trial testing the efficacy and tolerability of cannabis-derived medicine as treatment for pediatric epilepsy. The trial was conducted in partnership with The Hospital For Sick Children (SickKids) in Toronto, Canada and published promising results in August.